English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 903733      Online Users : 540
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14505


    Title: Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience
    Authors: Ting, YL;Su, YY;Chiang, NJ;Chao, YJ;Li, YJ;Huang, CJ;Liao, TK;Su, PJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT
    Contributors: National Institute of Cancer Research
    Abstract: Background: There is increasing evidence that neoadjuvant chemotherapy in stage III pancreatic cancer resulted in higher rate of conversion surgery and improved survival. This study aims to investigate the practice pattern and how initial treatment strategy impact the outcome of stage III pancreatic ductal adenocarcinoma (PDAC). Methods:During February 2013 to July 2020, 164 stage III PDAC patients treating at National Cheng Kung University Hospital were manually reviewed. This study is approved by the Institutional Review Board (A-ER-108-113) and followed the Declaration of Helsinki. Results:The 164 patients had a median age of 66 (range 27-84), a median albumin of 4.0 g/dl (range 2.5-5.0) and a median CA 199 of 356 U/ml (range 1.5-12000). We observed a paradigm shift with neoadjuvant chemotherapy being the major approach since 2016. The initial treatment strategy was neoadjuvant chemotherapy (NAC) in 127 patients (77.4%), upfront operation (OP) in 19 patients (11.6%) and concurrent chemotherapy (CCRT) in 18 patients (11.0%). The success rate of surgery was significantly higher in NAC group than OP and CCRT group (39% vs. 26% vs 22%). The prognosis was also significantly better in NAC group than OP and CCRT group with corresponding median overall survival (mOS) of 18.6, 9.7 and 9.0 months. For NAC group, the mOS of those with or without conversion surgery was 29.4 months and 14.5 months, respectively. The combination of S-1/leucovorin, oxaliplatin and gemcitabine (SLOG) was the most common used regimen (n=52) followed by modified FOLFIRINOX (n=22). Conclusions: Neoadjuvant chemotherapy was adapted as standard of care in our institute since 2016 and achieved a significantly higher success rate of conversion surgery and improved mOS in patients with stage III PDAC.
    Date: 2022-07
    Relation: Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
    Link to: http://dx.doi.org/10.1016/j.annonc.2022.05.319
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000834940400408
    Appears in Collections:[陳立宗] 會議論文/會議摘要
    [蔡慧珍] 會議論文/會議摘要
    [姜乃榕] 會議論文/會議摘要
    [蘇勇曄] 會議論文/會議摘要

    Files in This Item:

    File Description SizeFormat
    ISI000834940400408.pdf105KbAdobe PDF132View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback